Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity? - Wikidata - wikimedia - TriplyDB

Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?

Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?

http://www.wikidata.org/entity/Q47558056

about

Computational Molecular Docking and X-ray Crystallographic Studies of Catechins in New Drug Design Strategies

P2860

Q58692799-5BDF3CF4-34C1-466E-913D-1861BAAAE0E4

P2860

Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?

http://www.wikidata.org/entity/Q47558056

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?

@en

Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?

@nl

type

label

Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?

@en

Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?

@nl

prefLabel

Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?

@en

Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?

@nl

P1433

Q47558056-6B56B748-3C19-4F3A-9634-58A46ACD6D2B

P1476

Q47558056-78BCEB06-F8AC-4BBE-90C4-27BFF99FD2EE

P2093

Q47558056-159A1137-A49A-4C8E-A227-35647531CAC3

Q47558056-38C5F7F0-2EBF-42AC-BE10-BCAAB424C646

Q47558056-6EB192B0-B563-42D3-8CCE-2E715BAE86E4

Q47558056-9A90409D-613C-453C-9C0B-4D042155E756

Q47558056-CB3E5C70-0BB7-4E36-BEC1-8B98AEC861E1

P275

Q47558056-29898685-41A0-42F0-8506-D37CDD753CE6

P2860

Q47558056-0277B549-A3BF-4701-BE23-67D0780EFC4C

Q47558056-02FD556E-FD9C-4747-AD4F-2421C412A54E

Q47558056-10FE9CF3-338C-4DDD-A67E-8D9FC6EC84D8

Q47558056-1A335A5D-476B-4562-A468-62245A00FF7E

Q47558056-1CEFFDF5-DE3B-481D-8EDD-22FD7EBB612B

Q47558056-1D2EE5FE-2751-4E42-AE6B-C61DB8EDC418

Q47558056-2193C520-20D8-4E91-AA4D-8287999FCA1D

Q47558056-2E89A951-B7A6-49DE-ACA1-783E6D7F948D

Q47558056-2FE6DCAB-08B6-4E56-B9A4-767EDCFAD2A4

Q47558056-2FE8D872-8BE7-4BF6-B42D-C0BC32161ED2

P31

Q47558056-276BE319-4314-49E3-AADF-8672BB57DB43

Q47558056-59FA9ADB-558F-49E1-A473-DBFF7568C2B1

P356

Q47558056-0A7BC453-2F6B-4E10-A869-2A0D6ACC4298

P407

Q47558056-B5842A6F-8604-4E41-AC60-91B4FE7BC938

P433

Q47558056-E35D5DC2-94A6-4C5D-B5F7-57D5099C6C5D

P478

Q47558056-1E7C6F1B-1282-4D5E-9C92-8F300B8B8028

P5008

Q47558056-F90B5DC6-9842-4514-8D15-F1B13EE2321A

P577

Q47558056-E4F0E60F-8815-4E06-B7C5-2D711FBEE029

P698

Q47558056-09B57B33-9186-48D6-94AE-6A12A3AAF888

P921

Q47558056-331FB529-F279-4336-B8BB-50A44CB6FDEE

Q47558056-3F6002BC-B073-4FB6-8D78-8D1D181D742E

P932

Q47558056-AB8E3FCA-CC72-4378-9378-E25053EB2BEA

P356

P1433

International Journal of Molecular Sciences

P1476

Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?

@en

P2093

Ewa Skrzypczak-Jankun

http://www.w3.org/2001/XMLSchema#string

Jerzy Jankun

http://www.w3.org/2001/XMLSchema#string

Maja Matthews-Kozanecka

http://www.w3.org/2001/XMLSchema#string

Marzena Wyganowska-Świątkowska

http://www.w3.org/2001/XMLSchema#string

Teresa Matthews-Brzozowska

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress

Complementary and alternative therapies for Down syndrome

Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor

Principal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down Syndrome

Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines

Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity

Down Syndrome: Current Status, Challenges and Future Perspectives

Tissue inhibitors of metalloproteinases: evolution, structure and function

Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals

Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2

P31

scholarly article

P356

10.3390/IJMS19010248

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2018-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29342922

http://www.w3.org/2001/XMLSchema#string

P921

P932

5796196

http://www.w3.org/2001/XMLSchema#string